Study tracking HEMGENIX for hemophilia B
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study watches how well HEMGENIX works and how safe it is for people with hemophilia B who are getting the treatment. It also compares data from adults on standard factor IX shots.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hemophilia B and are receiving the commercial version of HEMGENIX.
- You signed a consent form within 3 months before or 6 months after starting HEMGENIX, or within 6 months of when the study started at your center.
- Or you are an adult (18 or older) with hemophilia B who is getting regular factor IX shots and are already in a registry like ATHN Transcends.
- You have not gotten HEMGENIX in a research study before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy (REGV131-LNP1265) that aims to let your body produce its own factor IX, reducing or stopping the need for regular infusions. It is for children and adults with severe hemophilia B who are already using factor IX replacement therapy.
This trial tests a single dose of ANB-002, an experimental therapy for hemophilia B. It aims to see if the drug is safe and effective for people with severe hemophilia B who have been treated with factor IX before and do not have inhibitors.
This study tests a new gene therapy called ANB-002 for men with severe hemophilia B (factor IX levels at or below 2%). The goal is to see if it's safe and how well it might help your blood clot normally.
This Phase 1 study tests a one-time gene therapy treatment (BBM-H901) for boys ages 12 to 18 with hemophilia B. It aims to see if the treatment is safe and can help the body make more clotting factor over time.
This gene therapy trial uses a modified virus to deliver a working copy of the gene that makes factor IX, the protein missing in hemophilia B. The goal is to help your body produce enough factor IX to reduce or prevent bleeding episodes, potentially reducing the need for regular factor IX infusions.
This study tests a one-time gene therapy (CSL222) for teenage boys with severe or moderately severe hemophilia B. It aims to help their bodies produce the clotting factor they need, potentially reducing or eliminating the need for regular factor infusions.
Hear when a new Hemophilia B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.